Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1200 of 1631 entries
View as:

Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination

Phase: N/A Priority: Normal
NCT ID: NCT01973868 Org: User:
Start: 11/21/13 End: 04/03/18 Due: 04/03/19

Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02605356 Org: User:
Start: 10/31/16 End: 07/31/21 Due: 07/31/22

Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study

Phase: N/A Priority: Normal
NCT ID: NCT02876718 Org: User:
Start: 08/11/16 End: 01/09/18 Due: 01/09/19

Sorafenib/Docetaxel Dose Escalation Trial

Phase: N/A Priority: Normal
NCT ID: NCT00562523 Org: User:
Start: 11/30/07 End: 03/31/09 Due: 03/31/10

Single/Multiple Dose Bioavailability Trial

Phase: N/A Priority: Normal
NCT ID: NCT00751556 Org: User:
Start: 02/29/08 End: 03/31/08 Due: 03/31/09

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

Phase: N/A Priority: Normal
NCT ID: NCT00362232 Org: User:
Start: 06/30/06 End: 01/31/08 Due: 01/31/09

Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006

Phase: N/A Priority: Normal
NCT ID: NCT00119639 Org: User:
Start: 06/30/05 End: 12/31/05 Due: 12/31/06

A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

Phase: N/A Priority: Normal
NCT ID: NCT00699751 Org: User:
Start: 06/30/08 End: 02/28/14 Due: 02/28/15

Physical Activity and Fatigue in Early Multiple Sclerosis (MS)

Phase: N/A Priority: Normal
NCT ID: NCT00882453 Org: User:
Start: 08/31/06 End: 03/31/11 Due: 03/31/12

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02122913 Org: User:
Start: 05/04/14 End: 04/09/21 Due: 04/09/22

SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)

Phase: N/A Priority: Normal
NCT ID: NCT00879008 Org: User:
Start: 12/31/09 End: 08/31/10 Due: 08/31/11

Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02581878 Org: User:
Start: 11/20/15 End: 11/26/19 Due: 11/26/20

An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib

Phase: N/A Priority: Normal
NCT ID: NCT05594147 Org: User:
Start: 10/31/22 End: 04/21/23 Due: 04/21/24

Efficacy of a Single Dose of Aspirin vs. Acetaminophen in Tension Type Headache

Phase: N/A Priority: Normal
NCT ID: NCT01552798 Org: User:
Start: 03/12/12 End: 06/04/12 Due: 06/04/13

Outdoor-Use Test for Sunscreen Products in Children Ages 3 to 9 Years Old

Phase: N/A Priority: Normal
NCT ID: NCT02831478 Org: User:
Start: 07/09/16 End: 07/10/16 Due: 07/10/17

Switching Study From Warfarin to Rivaroxaban

Phase: N/A Priority: Normal
NCT ID: NCT01507051 Org: User:
Start: 11/30/08 End: 11/30/09 Due: 11/30/10

Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01795872 Org: User:
Start: 09/30/13 End: 06/30/14 Due: 06/30/15

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT01029340 Org: User:
Start: 12/31/09 End: 03/31/13 Due: 03/31/14

Efficacy of ONE A DAY Weightsmart Advanced Versus Caffeine and Placebo on Energy Expenditure, Thermogenesis and Perceived Energy Levels in Women.

Phase: N/A Priority: Normal
NCT ID: NCT00781586 Org: User:
Start: 10/02/07 End: 04/21/08 Due: 04/21/09

Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation

Phase: N/A Priority: Normal
NCT ID: NCT01014247 Org: User:
Start: 11/30/09 End: 06/30/10 Due: 06/30/11

A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function

Phase: N/A Priority: Normal
NCT ID: NCT00478881 Org: User:
Start: 08/31/07 End: 11/30/08 Due: 11/30/09

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

Phase: N/A Priority: Normal
NCT ID: NCT02138812 Org: User:
Start: 05/09/14 End: 10/02/17 Due: 10/02/18

Cardiovascular Disease Risk Factors Prevalence Among Bayer's Employees in São Paulo, Brazil

Phase: N/A Priority: Normal
NCT ID: NCT02055651 Org: User:
Start: 08/31/13 End: 10/31/16 Due: 10/31/17

A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.

Phase: N/A Priority: Normal
NCT ID: NCT03715725 Org: User:
Start: 10/31/18 End: 01/20/20 Due: 01/20/21

Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer

Phase: N/A Priority: Normal
NCT ID: NCT00786422 Org: User:
Start: 05/31/09 End: 06/30/11 Due: 06/30/12